Last updated: September 3, 2026
Tirapazamine is a hypoxia-activated small-molecule anticancer agent that has not reached regulatory approval. Its principal late-stage programs in non-small-cell lung cancer and locally advanced head and neck cancer failed to demonstrate sufficient clinical benefit. Development appears commercially inactive, with no FDA-approved product, no Orange Book-listed tirapazamine product, no established generic launch pathway, and no identifiable current revenue base.
The base-case market projection is therefore zero through 2030. A commercial opportunity would require a new sponsor, a biomarker-driven development strategy, new clinical trials and a regulatory filing. That pathway would carry high technical and commercial risk.
What is tirapazamine and how does it work?
Tirapazamine, also known as 3-amino-1,2,4-benzotriazine 1,4-dioxide, is a hypoxia-activated prodrug. It is designed to become cytotoxic after enzymatic reduction in low-oxygen tumor tissue. The activated compound generates DNA-damaging radical species, with the intended effect of selectively killing hypoxic cancer cells that are relatively resistant to radiotherapy and some chemotherapy.
The development thesis was strongest in solid tumors with substantial hypoxic regions, including:
- Head and neck squamous cell carcinoma
- Non-small-cell lung cancer
- Cervical cancer
- Pancreatic cancer
- Prostate cancer
- Other locally advanced solid tumors treated with radiotherapy
The clinical rationale was to combine tirapazamine with cisplatin and radiotherapy. Radiotherapy is less effective in hypoxic tissue, while tirapazamine was intended to target that resistant tumor compartment. Reviews of tumor hypoxia identified tirapazamine as one of the leading early hypoxia-targeting agents, but also described limitations involving tumor oxygen heterogeneity, drug activation, pharmacokinetics and toxicity [1].
What is the current development status of tirapazamine?
Tirapazamine is a discontinued or commercially inactive development asset rather than an active late-stage drug candidate.
Development timeline
| Period |
Development event |
Commercial significance |
| 1980s-1990s |
Preclinical and early clinical development of tirapazamine |
Established hypoxia-activated prodrug concept |
| 1990s-early 2000s |
Phase I and phase II studies in multiple solid tumors |
Supported combination development with cisplatin and radiotherapy |
| 2005 |
Novacea obtained development and commercialization rights from Sanofi-Aventis |
Shifted commercial sponsorship to a biotechnology company |
| 2007 |
Phase III non-small-cell lung cancer study reported no material benefit |
Major setback for systemic oncology development |
| 2010 |
Phase III head and neck cancer trial reported no improvement in the primary clinical outcomes |
Effectively ended the leading registrational strategy |
| 2011 onward |
No successful regulatory filing or approval emerged |
Program lost commercial momentum |
| Through 2024 |
No FDA approval, marketed product or active global commercial franchise identified |
No current product revenue |
Novacea was the principal later-stage commercial sponsor associated with tirapazamine. The company’s program was built around combining the drug with platinum chemotherapy and radiotherapy. The failure of the principal phase III studies materially reduced the value of the asset and weakened the case for additional broad oncology development.
Why did the phase III tirapazamine trials fail?
The principal clinical problem was a failure to translate the hypoxia mechanism into a clinically meaningful survival or disease-control advantage.
Non-small-cell lung cancer
A randomized phase III study evaluated tirapazamine plus cisplatin against cisplatin-based chemotherapy in advanced non-small-cell lung cancer. The study did not show the expected improvement in overall survival or progression outcomes. The results did not support tirapazamine as a new standard component of treatment [2].
The trial exposed several development risks:
- Tumor hypoxia was not used as a validated patient-selection biomarker.
- The treatment effect appeared inconsistent across disease subgroups.
- Systemic disease burden may have limited the benefit of a tumor-localized hypoxia mechanism.
- Added toxicity and treatment complexity reduced the commercial attractiveness of the regimen.
- Cisplatin-based control therapy remained a strong comparator.
Locally advanced head and neck cancer
The TROG 02.02 phase III study evaluated tirapazamine with cisplatin and radiotherapy in locally advanced head and neck squamous cell carcinoma. The trial did not demonstrate the expected improvement in locoregional control or survival compared with standard cisplatin chemoradiotherapy [3].
This result was especially damaging because head and neck cancer was a logical setting for tirapazamine. The treatment platform already included radiotherapy, a modality with a clear biological relationship to tumor oxygenation. Failure in this setting reduced the probability that tirapazamine would succeed in other unselected solid-tumor populations.
What is the FDA regulatory status of tirapazamine?
Tirapazamine has no FDA approval and no U.S. marketing authorization.
| Regulatory issue |
Status |
| FDA approval |
None identified |
| New Drug Application |
No approved application identified |
| Biologics License Application |
Not applicable |
| FDA breakthrough designation |
None identified |
| FDA accelerated approval |
None identified |
| Orange Book listing |
No approved tirapazamine product identified |
| U.S. marketed dosage form |
None |
| Generic approval pathway |
No active commercial pathway identified |
Tirapazamine is a conventional small molecule, not a biologic. Any future U.S. product would generally require an NDA supported by a new clinical and manufacturing package. A generic applicant could use an abbreviated new drug application only after an approved reference product existed and relevant regulatory requirements were satisfied. Since tirapazamine has no approved reference product, there is currently no conventional ANDA-based market.
What patents protect tirapazamine?
The original composition-of-matter and early development patent estate is old relative to modern pharmaceutical exclusivity periods. Tirapazamine was disclosed and developed decades ago, making the core patent rights unlikely to provide meaningful remaining exclusivity in major markets.
Patent estate assessment
| Patent category |
Current assessment |
| Core chemical composition |
Likely expired or commercially exhausted |
| Salt and solid-state patents |
No established commercial protection identified |
| Formulation patents |
No approved commercial formulation estate identified |
| Method-of-use patents |
Historical clinical-use protection may have existed, but no current marketed-use barrier is established |
| Manufacturing patents |
Process patents could have had later expiry dates, but no active manufacturing barrier is publicly established |
| U.S. Orange Book patents |
None because no approved product is listed |
| Patent term extension |
No approved U.S. product identified for which extension could apply |
| Patent litigation |
No active, commercially material patent litigation identified |
The key distinction is between historical patent ownership and current enforceable commercial exclusivity. Tirapazamine may have been covered by early patent families involving the chemical entity, pharmaceutical compositions or anticancer uses. Those rights do not create a current branded monopoly if their terms have expired.
Sanofi-Aventis and Novacea were associated with different stages of development and commercialization. Historical licensing arrangements therefore matter for chain-of-title analysis, but they do not by themselves establish current market exclusivity.
Are there formulation patents or method-of-use patents for tirapazamine?
Historical patent protection likely focused on the chemical compound, pharmaceutical compositions and use of tirapazamine as an anticancer agent. No formulation has achieved sufficient regulatory or commercial status to create a durable product-specific barrier.
Formulation protection
No approved oral, injectable or depot tirapazamine product exists in the United States. The absence of a marketed formulation means there is no current branded delivery system comparable to extended-release, liposomal or antibody-drug-conjugate products.
A future sponsor could seek protection for:
- A new injectable formulation
- A tumor-targeted delivery system
- A combination regimen
- A biomarker-defined patient population
- A new dosing schedule
- A formulation designed to improve exposure or reduce systemic toxicity
Such patents would be vulnerable to validity and obviousness challenges if they rely on known tirapazamine chemistry or previously studied combinations.
Method-of-use protection
A future method-of-use patent could focus on hypoxic tumors selected using imaging, gene-expression signatures, hypoxia-related proteins or other biomarkers. This would be more commercially relevant than a broad historical claim to treating cancer with tirapazamine.
Method-of-use protection would not prevent all competitors from developing the molecule. Its value would depend on:
- Whether the biomarker is clinically validated.
- Whether the FDA accepts the biomarker as part of the development strategy.
- Whether physicians can identify eligible patients reliably.
- Whether the claim covers a commercially important treatment population.
When does tirapazamine lose exclusivity?
Tirapazamine has no meaningful current regulatory exclusivity period because it has never received FDA approval.
The likely status of the core patent estate is as follows:
- Original compound protection: historical and likely expired.
- Historical clinical-use patents: likely expired or limited in scope.
- Formulation protection: no commercially relevant approved product identified.
- New-use protection: potentially available only for genuinely novel, non-obvious clinical applications.
- Regulatory exclusivity: none currently active.
A new sponsor would not inherit a fresh exclusivity period merely by acquiring the old molecule. New patent rights could arise from new clinical uses, formulations or manufacturing methods, but those rights would need to satisfy patentability requirements and would not restore the broad exclusivity that normally supports a first approval of a new chemical entity.
Has tirapazamine faced Paragraph IV challenges or generic competition?
No commercially significant Paragraph IV challenge or approved generic competition has been identified.
The reason is structural. Paragraph IV litigation typically arises when an ANDA applicant seeks approval for a generic equivalent to an approved reference drug while challenging listed patents. Tirapazamine has no approved reference product and no Orange Book listing. The relevant competitive risk is therefore not an immediate generic launch. It is the possibility that another sponsor could develop a different hypoxia-activated prodrug or a new targeted therapy for the same patient population.
Is tirapazamine exposed to biosimilar competition?
No. Biosimilar risk is not applicable because tirapazamine is a small-molecule chemical drug rather than a biologic.
The relevant competitive threats are:
- Generic small-molecule oncology drugs if tirapazamine were ever approved.
- Other hypoxia-activated prodrugs.
- Radiosensitizers.
- Immunotherapy combinations.
- Molecularly targeted therapies.
- Improved radiotherapy and image-guided treatment.
- Biomarker-selected approaches that exclude tirapazamine.
What licensing deals affected tirapazamine?
Sanofi-Aventis was associated with tirapazamine’s earlier commercial development, while Novacea became a later development sponsor after obtaining rights. Novacea’s involvement aligned tirapazamine with a biotechnology financing and partnering model rather than a continuing large-pharmaceutical franchise.
The later phase III failures reduced the value of the licensing position. No current major pharmaceutical commercialization agreement has been identified. There is also no established active licensee with a marketed product or late-stage regulatory program.
The historical licensing structure remains relevant to diligence because a future transaction would need to address:
- Chain of title for patents and know-how.
- Rights to clinical data.
- Rights to manufacturing processes.
- Obligations under terminated or surviving agreements.
- Ownership of new formulations or biomarker applications.
- Any retained rights held by the original originator.
What is the competitive landscape for tirapazamine?
Tirapazamine competes conceptually with other strategies designed to overcome hypoxia-related treatment resistance.
| Competitive category |
Examples or status |
Relative implication |
| Hypoxia-activated prodrugs |
Evofosfamide and other investigational agents |
Direct mechanistic competition |
| Radiotherapy sensitizers |
Platinum agents and newer radiosensitizers |
Established treatment infrastructure |
| Immunotherapy |
Checkpoint inhibitors in head and neck and lung cancer |
Strong standard-of-care competition |
| Targeted therapy |
Molecularly selected therapies |
Better-defined patient selection |
| Hypoxia imaging |
PET and molecular imaging approaches |
Could support biomarker-based revival |
| Local therapies |
Surgery, stereotactic radiotherapy and image-guided treatment |
Reduces systemic-treatment opportunity |
Evofosfamide is a separate hypoxia-activated prodrug and should not be treated as a tirapazamine product or successor. Its clinical development history illustrates the broader difficulty of proving benefit from hypoxia-activated therapy in heterogeneous solid tumors.
What generic launch risks exist for tirapazamine?
There is no near-term generic launch risk because there is no approved branded product to copy. If tirapazamine were successfully redeveloped and approved, generic exposure would become significant over time because:
- The molecule is chemically defined.
- Manufacturing is likely less complex than biologic production.
- The historical core patent estate is old.
- New-use patents may cover only narrow patient populations.
- A formulation patent may not block alternative dosage forms.
- Oncology physicians are accustomed to substitutable small-molecule therapies.
The commercial protection of any future product would depend more on new clinical data and narrow biomarker claims than on the historical compound patent.
What is the market projection for tirapazamine through 2030?
Tirapazamine has no current product sales. The base-case revenue forecast is zero through 2030 because no active approval, launch plan or late-stage sponsor has been established.
Scenario-based market projection
| Scenario |
Probability assessment |
2030 annual sales outlook |
Required conditions |
| Base case: no redevelopment |
Highest |
$0 |
Program remains inactive |
| Academic or regional revival |
Low |
Below $25 million |
Small investigator-led studies or limited-access use |
| Biomarker-driven redevelopment |
Low |
$50 million-$150 million |
New sponsor, validated biomarker and positive phase II/III data |
| Broad oncology approval |
Very low |
$150 million-$300 million |
Clear survival benefit, broad label and commercial manufacturing |
| Generic or low-price repurposing |
Very low |
Commercially immaterial |
Approval without durable exclusivity |
These are strategic scenarios, not reported market forecasts. The addressable population is theoretically large because hypoxia occurs across multiple solid tumors. The practical market is much smaller because the drug lacks approval, validated patient selection, current commercial sponsorship and demonstrated clinical benefit.
A successful revival would most likely target a narrow, biomarker-selected population rather than all patients with lung, head and neck or cervical cancer. That approach could improve clinical performance but would constrain volume and require diagnostic development.
What would be required for a tirapazamine revival?
A credible restart would need to depart from the original unselected combination strategy.
Technical requirements
- A validated method to identify tumors with clinically actionable hypoxia.
- Evidence that tirapazamine exposure reaches the hypoxic tumor compartment.
- A dosing regimen that avoids unacceptable systemic toxicity.
- A combination strategy compatible with current standards of care.
- A prospective biomarker plan accepted by regulators.
Regulatory requirements
- A new FDA development program.
- Modern pharmacokinetic and pharmacodynamic characterization.
- New safety data or a clear justification for reliance on historical data.
- A registrational trial using a clinically meaningful endpoint.
- A manufacturing package for a reproducible pharmaceutical product.
Commercial requirements
- A sponsor with sufficient capital for a new oncology program.
- Clear ownership of patents, data and manufacturing rights.
- Differentiation from other hypoxia-activated agents.
- A reimbursement case based on survival, quality of life or reduced treatment burden.
- A strategy for generic competition after any new patent term expires.
Key Takeaways
- Tirapazamine is not FDA-approved and has no Orange Book-listed product.
- The main phase III programs in non-small-cell lung cancer and head and neck cancer failed to show sufficient benefit.
- Historical licensing involved Sanofi-Aventis and Novacea, but no active commercial franchise is established.
- The core compound patent estate is old and unlikely to provide meaningful current exclusivity.
- Paragraph IV and biosimilar risks are not currently relevant.
- The drug has no current revenue base.
- The base-case market projection is $0 through 2030.
- A revival would require biomarker-selected development, new clinical evidence and new patentable formulation or use claims.
- The most likely commercial outcome is continued inactivity rather than generic entry or a branded launch.
FAQs About Tirapazamine
Is tirapazamine still being developed for cancer?
No active global late-stage commercial development program has been established through 2024. Historical development focused on lung and head and neck cancer, but the principal phase III studies were unsuccessful.
Did tirapazamine receive FDA approval?
No. Tirapazamine has not received FDA approval and is not listed as an approved product in the Orange Book.
What company owned tirapazamine?
Sanofi-Aventis was associated with earlier development, while Novacea later obtained rights and sponsored major clinical programs. Current commercial ownership and active development rights have not produced a marketed product.
Is tirapazamine the same drug as evofosfamide?
No. Both are hypoxia-activated prodrugs, but evofosfamide and tirapazamine are different chemical entities and separate development programs.
Could tirapazamine be revived with a biomarker strategy?
Possibly, but a revival would require new evidence that biomarker-selected patients derive a clinically meaningful benefit. Historical unselected phase III failures make a conventional broad-label restart commercially unlikely.
References
-
Brown, J. M., & Wilson, W. R. (2004). Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer, 4(6), 437-447.
-
von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Ghielmini, M., Mazieres, J., Reck, M., Rey, A., Rischin, D., & Rittmeyer, A. (2007). Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A randomized phase III study. Journal of Clinical Oncology.
-
Rischin, D., Hicks, R. J., Fisher, R., Binns, D., Corry, J., Porceddu, S., Peters, L. J., & TROG Head and Neck Trial Management Committee. (2010). Prognostic significance of hypoxia measured by fluoromisonidazole positron emission tomography in locally advanced head and neck cancer treated with chemoradiotherapy incorporating tirapazamine. Journal of Clinical Oncology.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
ClinicalTrials.gov. (2024). Studies involving tirapazamine. U.S. National Library of Medicine.
-
Novacea, Inc. (2008). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
